FDA approves Medtronic left-heart lead for CRT devices
The FDA has approved Medtronic's Attain Ability left-heart lead for use with cardiac resynchronization therapy (CRT) devices for heart failure patients, which the company is immediately making available for purchase in the U.S.
The Attain Ability left-heart lead (Model 4196) incorporates insulation material developed by NASA Langley Research Center that was previously evaluated for space applications, high-performance engines and harsh environments, according to the Minneapolis-based company. The application marks the first time a NASA-developed material has been used in this kind of implantable medical device.
Also, Medtronic said that Attain Ability can be delivered by an inner catheter, the Attain Select II, allowing physicians to place the lead in difficult-to-reach areas of the heart.
The Attain Ability left-heart lead (Model 4196) incorporates insulation material developed by NASA Langley Research Center that was previously evaluated for space applications, high-performance engines and harsh environments, according to the Minneapolis-based company. The application marks the first time a NASA-developed material has been used in this kind of implantable medical device.
Also, Medtronic said that Attain Ability can be delivered by an inner catheter, the Attain Select II, allowing physicians to place the lead in difficult-to-reach areas of the heart.